Human Transmission of Blastocystis by Fecal Microbiota Transplantation Without Development of Gastrointestinal Symptoms in Recipients.
Human Transmission of Blastocystis by Fecal Microbiota Transplantation Without Development of Gastrointestinal Symptoms in Recipients.
复制标题
粪便微生物群移植中胚泡的人类传播，而没有受体中胃肠道症状的发展。
DOI：
10.1093/cid/ciz1122
复制
发表时间：
2020-12-17
期刊：
影响因子：
--
通讯作者：
Netherlands Donor Feces Bank (NDFB) Study Group
中科院分区：
文献类型：
--
作者：
Terveer EM;van Gool T;Ooijevaar RE;Sanders IMJG;Boeije-Koppenol E;Keller JJ;Bart A;Kuijper EJ;Netherlands Donor Feces Bank (NDFB) Study Group
患有多重复发性艰难梭菌感染（rCDI）的患者使用健康供体提供的粪便通过粪便微生物群移植（FMT）进行治疗。供体的芽囊原虫定殖被认为是排除标准，而其致病性仍在争论中。在我们的粪便库中引入芽囊原虫的分子筛查，确定了2名先前显微镜检查阴性但聚合酶链反应（PCR）阳性的供体。通过PCR和亚型（ST）分析，评估了16份FMT前后粪便患者样本中芽囊原虫对患者的潜在传播。此外，还评估了rCDI（n = 31）治疗的临床结局以及胃肠道症状的发生。有1名供体携带囊胚ST 1，另一名携带ST 3。所有患者在FMT前的囊胚检测结果均为阴性。在FMT后20.5天的中位诊断中，16例患者中有8例（50%）发生了芽囊原虫的肠道定植，其ST序列与其各自的供体相同。使用含有囊胚的粪便悬浮液治疗31例rCDI患者，FMT成功率为84%。该成功率与移植囊胚菌阴性供体粪便的患者（93%，76/82）无统计学差异。移植囊胚菌属阳性供体粪便的患者在FMT后第一周、3周或数月内的肠道主诉没有任何显著差异。我们通过FMT证实了囊胚ST 1和ST 3从供体到患者的首次传播。这不会导致胃肠道疾病或对rCDI治疗结局产生任何显著影响。在50%的患者中发生了通过来自定殖供体的粪便微生物群移植（FMT）传播囊胚的情况。转移不会导致胃肠道症状的发展，也不会影响复发性艰难梭菌感染患者的FMT治疗结果。
Patients with multiple recurrent Clostridioides difficile infections (rCDI) are treated with fecal microbiota transplantation (FMT), using feces provided by healthy donors. Blastocystis colonization of donors is considered an exclusion criterion, whereas its pathogenicity is still under debate. The introduction of molecular screening for Blastocystis sp. at our stool bank identified 2 donors with prior negative microscopies but positive polymerase chain reactions (PCRs). Potential transmission of Blastocystis sp. to patients was assessed on 16 fecal patient samples, pre- and post-FMT, by PCR and subtype (ST) analyses. In addition, clinical outcomes for the treatment of rCDI (n = 31), as well as the development of gastrointestinal symptoms, were assessed. There was 1 donor who carried Blastocystis ST1, and the other contained ST3. All patients tested negative for Blastocystis prior to FMT. With a median diagnosis at 20.5 days after FMT, 8 of 16 (50%) patients developed intestinal colonization with Blastocystis, with identical ST sequences as their respective donors. Blastocystis-containing fecal suspensions were used to treat 31 rCDI patients, with an FMT success rate of 84%. This success rate was not statistically different from patients transferred with Blastocystis sp.–negative donor feces (93%, 76/82). Patients transferred with Blastocystis sp.–positive donor feces did not report any significant differences in bowel complaints in the first week, after 3 weeks, or in the months following FMT. We demonstrated the first transmission of Blastocystis ST1 and ST3 from donors to patients by FMT. This did not result in gastrointestinal symptomatology or have any significant effect on rCDI treatment outcomes. Transmission of Blastocystis by fecal microbiota transplantation (FMT) from colonized donors occurred in 50% of patients. Transfer did not result in development of gastrointestinal symptoms or affect the outcome of the FMT treatment in patients with recurrent Clostridioides difficile infections.
登录
查看更多内容
影响因子：
14.2
作者：
Debast, S. B.;Bauer, M. P.;Kuijper, E. J.
通讯作者：
Kuijper, E. J.
影响因子：
4.2
作者：
Andersen, Lee O'Brien;Bonde, Ida;Stensvold, Christen Rune
通讯作者：
Stensvold, Christen Rune
影响因子：
12.6
作者：
Krogsgaard, Laura Rindom;Engsbro, Anne Line;Bytzer, Peter
通讯作者：
Bytzer, Peter
影响因子：
15.5
作者：
Nash AK;Auchtung TA;Wong MC;Smith DP;Gesell JR;Ross MC;Stewart CJ;Metcalf GA;Muzny DM;Gibbs RA;Ajami NJ;Petrosino JF
通讯作者：
Petrosino JF
DOI：
10.1016/j.ijantimicag.2019.03.008
发表时间：
2019-05-01
影响因子：
10.8
作者：
Davido, Benjamin;Batista, Rui;Caballero, Silvia
通讯作者：
Caballero, Silvia